{"database": "lobbying", "table": "lobbying_activities", "rows": [[2463364, "fa6dfd70-58b1-4fda-9ae3-31f9a7ea52ea", "Q2", "AMERICAN PHARMACISTS ASSOCIATION", 3071, "AMERICAN PHARMACISTS ASSOCIATION", 2020, "second_quarter", "HCR", "H.R. 2482/S. 2074 Mainstreaming Addiction Treatment Act of 2019-\nTo amend section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)) to eliminate the separate registration requirement for dispensing narcotic drugs in schedule III, IV, or V (such as buprenorphine) for maintenance or detoxification treatment, and for other purposes.\nH.R. 6800 - This bill responds to the COVID-19 (i.e., coronavirus disease 2019) outbreak and its impact on the economy, public health, state and local governments, individuals, and businesses.", "HOUSE OF REPRESENTATIVES,SENATE", null, 34000, 0, 0, "2020-07-10T12:21:58.880000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2463364"], "units": {}, "query_ms": 16.262038028798997, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}